The Influence of Indomethacin on Some Pharmacological Actions of Atenolol

  • A. Salvetti
  • R. Pedrinelli
  • A. Magagna
  • B. Abdel-Haq


The usefulness of β-adrenoreceptor blocking agents in the treatment of hypertensive patients is now well known,1,2 but their mechanism(s) of action is not well established.2 Recently indomethacin, a potent inhibitor of prostaglandin (PG) synthesis,3,4 was found to reduce the hypotensive action of nonselective β-adrenoreceptor blocking agents in rats,5 rabbits,6 and humans.7–9 On this basis it has been proposed that an enhanced formation of prostaglandins may contribute to the hypotensive effect of these drugs, and this hypothesis has now received further support by the finding that propranolol increases the net production of PGE2 in the rat mesentery.10 Since, to our knowledge, no report exists showing that such a mechanism may be operative during treatment with cardioselective β-adrenoreceptor blocking agents, we decided to study this possibility in patients with uncomplicated essential hypertension treated with atenolol, a well-known cardioselective β-blocker.11


Plasma Renin Activity Prostaglandin Synthesis Urinary Sodium Excretion Hypotensive Action Renal Perfusion Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lewis P: The essential action of propranolol in hypertension. Am J Med 60: 837–852, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    Lorimer AR, Dunn FG, Jones JV, et al: Beta adrenoreceptor blockade in hypertension. Am J Med 60: 877–885, 1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Flower K, Gryglewski R, Herbaczynska-Cedro K, et al: Effects of antiinflammatory drugs on prostaglandin biosynthesis. Nature London New Biol 238: 104–106, 1972.Google Scholar
  4. 4.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature London New Biol 231: 232–235, 1971.Google Scholar
  5. 5.
    Campbell WB, Zimmer JA: Effect of prostaglandin synthesis inhibition on the antihypertensive activity of propranolol in spontaneously hypertensive rat, in Seventh Scientific Meeting of the International Society of Hypertension, New Orleans, Louisiana, May 11–14, 1980, p 16.Google Scholar
  6. 6.
    Durao U, Rico GT: Modification by indomethacin of the blood pressure lowering effect of pindolol and propranolol in conscious rabbits. Eur J Pharmacol 43: 377–381, 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Watkins J, Abbott EC, Hensby CN, et al: Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J 281: 702–705, 1980.PubMedCrossRefGoogle Scholar
  8. 8.
    Lopez-Ovejero JA, Weber MA, Drayer JI, et al: Effects of indomethacin alone and during diuretic or beta-adrenoreceptor blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Mol Med 55: 203s - 205s, 1978.Google Scholar
  9. 9.
    Salvetti A, Arzilli F, Beggi P, et al: Interaction between oxprenolol and indomethacin on blood pressure control of essential hypertensive patients, in Eight Scientific Meeting of the International Society of Hypertension, Milan, Italy, 31st May-3rd June,1981 ABS 392.Google Scholar
  10. 10.
    Jackson EK, Campbell WB: A possible antihypertensive mechanism of propranolol: Antagonism of angiotensin II enhancement of sympathetic nervous transmission through prostaglandins. Hypertension 3: 23–33, 1981.PubMedGoogle Scholar
  11. 11.
    Heel RC, Brogden RN, Speight TM: Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17: 425–460, 1979.PubMedCrossRefGoogle Scholar
  12. 12.
    Frölich JC, Hollifield JW, Michelakis AM, et al: Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects; independence of sodium retention. Circ Res 44: 781–787, 1979.PubMedGoogle Scholar
  13. 13.
    Pedrinelli R, Arzilli F, Cavasinni L, et al: The effect of indomethacin on plasma renin activity and urinary aldosterone of patients with essential hypertension. J Endocrinol Invest 1: 315–320, 1980.Google Scholar
  14. 14.
    Brater DC: The effect of indomethacin on salt and water homeostasis. Clin Pharmacol Ther 25: 322–330, 1979.PubMedGoogle Scholar
  15. 15.
    Malvano R, Zucchelli GL, Rosa U, et al: Measurement of plasma renin activity by angiotensin I radioimmunoassay (I): An assessment of some methodological aspects. J Nucl Biol Med 16: 24–31, 1972.PubMedGoogle Scholar
  16. 16.
    Malvano R, Orlandini S, Cozzani P, et al: Methodological simplications in radioimmunoassay of urinary aldosterone. Clin Chim Acta 66: 331–334, 1976.PubMedCrossRefGoogle Scholar
  17. 17.
    Malvano R, Gandolfi C, Giannessi P, et al: Radioimmunoassay of aldosterone in crude plasma extracts. J Nucl Biol Med 20: 37–45, 1976.PubMedGoogle Scholar
  18. 18.
    Förster W, Taube CH, Block HU, et al: In vitro and in vivo effects of antihypertensive drugs on PG metabolism in different organs. Adv Prost Thromb Res 7: 811–813, 1980.Google Scholar
  19. 19.
    Güllner HG, Lake CR, Bartter FC: Effect of inhibition of prostaglandin synthesis on sympathetic nervous system function in man. J Clin Endocrinol Metab 49: 552–556, 1979.PubMedCrossRefGoogle Scholar
  20. 20.
    Jones DH, Daniel J, Hamilton CA, et al: Plasma noradrenaline concentration in essential hypertension during long term 13-adrenoreceptor blockade with oxprenolol. Br J Clin Pharmacol 9: 27–31, 1980.PubMedGoogle Scholar
  21. 21.
    Morganti A, Pickering TG, Lopez-Ovejero JA: Contrasting effects of acute beta-blockade with propranolol on plasma catecholamines and renin in essential hypertension: A possible basis for the delayed antihypertensive response. Am Heart J 98: 490–494, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Levine L, Moskowitz MA: a-and ß-adrenergic stimulation of arachidonic acid methabolism in cells in culture. Proc Nat Acad Sci USA 76: 6632–6636, 1979.PubMedCrossRefGoogle Scholar
  23. 23.
    Horton EW: Prostaglandins at adrenergic nerve endings. Br Med Bull 29: 148–151, 1973.PubMedGoogle Scholar
  24. 24.
    Moncada S, Vane JR: The pharmacology and clinical potential of prostacyclin, in Proceedings of the First World Conference on Clinical Pharmacology and Therapeutics, London, 3–9 August 1980. New York, MacMillan, pp 15–32.Google Scholar
  25. 25.
    Patrono C, Pugliese F: The involvement of arachidonic acid metabolism in the control of renin release. J Endocrinol Invest 3: 193–201, 1980.PubMedGoogle Scholar
  26. 26.
    Zanchetti A: Neural regulation of renin release. Experimental evidence and clinical implications in arterial hypertension. Circulation 56: 691–698, 1977.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • A. Salvetti
    • 1
  • R. Pedrinelli
    • 1
  • A. Magagna
    • 1
  • B. Abdel-Haq
    • 1
  1. 1.Clinica Medica IUniversity of PisaPisaItaly

Personalised recommendations